ImmunityBio Shares Rise After 'Significant' Update on Bladder Cancer Treatment

MT Newswires Live11-20 03:16

ImmunityBio's (IBRX) shares rose past 6.1% in recent Tuesday trading after the company reported a "significant milestone" the trial of a bladder cancer treatment called Anktiva.

As of November, 100 patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, were treated with Anktiva, or nogapendekin alfa inbakicept-pmln, combined with BCG, showing a 71% complete response rate, the company said. The durable response lasted up to 54 months in some patients.

"This significant milestone underscores the potential of Anktiva to provide durable responses in patients with limited treatment options," the company said.

The data will be submitted to the European Medicines Agency for approval in the EU, expected in Q4, the company said.

Price: 5.32, Change: +0.31, Percent Change: +6.09

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment